Fluperlapine

Fluperlapine
Clinical data
ATC code	none;
Identifiers
	IUPAC name 3-fluoro-6-(4-methylpiperazin-1-yl)-11H-dibenzo[b,e]azepine;
CAS Number	67121-76-0 ;
PubChem CID	49381;
ChemSpider	44882 ;
UNII	EWG253M961;
ChEMBL	ChEMBL63756 ;
CompTox Dashboard (EPA)	DTXSID2046123 ;
Chemical and physical data
Formula	C19H20FN3
Molar mass	309.388 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc4ccc3c(/N=C(/N1CCN(C)CC1)c2ccccc2C3)c4;
	InChI InChI=1S/C19H20FN3/c1-22-8-10-23(11-9-22)19-17-5-3-2-4-14(17)12-15-6-7-16(20)13-18(15)21-19/h2-7,13H,8-12H2,1H3 ; Key:OBWGMKKHCLHVIE-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fluperlapine (NB 106-689), also known as fluoroperlapine, is a morphanthridine (11H-dibenzo[b,e]azepine) atypical antipsychotic with additional antidepressant and sedative effects. It was first synthesized in 1979, and then subsequently studied in animals and humans in 1984 and beyond, but despite demonstrating efficacy in the treatment of a variety of medical conditions including schizophrenia, psychosis associated with Parkinson's disease, depressive symptoms, and dystonia, it was never marketed. This was perhaps due to its capacity for producing potentially life-threatening agranulocytosis, similarly to clozapine, which it closely resembles both structurally and pharmacologically.